Literature DB >> 10082588

Interferon regulatory factor 2 represses the Epstein-Barr virus BamHI Q latency promoter in type III latency.

L Zhang1, J S Pagano.   

Abstract

Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1) is the essential protein for maintenance of the EBV episome and establishment of latency. The BamHI Q promoter (Qp) is used for the transcription of EBNA-1 mRNA in type I and type II latency, which are EBV infection states exemplified by Burkitt's lymphoma and nasopharyngeal carcinoma. However, Qp is inactive in type III latency, and other promoters (the BamHI C promoter and/or the BamHI W promoter) are used for EBNA-1. The involvement of interferon regulatory factors (IRFs) in the regulation of Qp is suggested by the presence of an essential interferon-stimulated response element (ISRE) in the promoter. In this work, expression of IRF-2 is shown to be inversely associated with Qp status, i.e., IRF-2 levels are high in type III latency (when Qp is inactive) and low in type I latency (when Qp is active). Also, IRF-2 is identified by electrophoretic mobility shift assay as the major protein binding to the Qp ISRE in type III latency. In transient transfection assays, IRF-2 represses the activity of Qp-reporter constructs. Overexpression of IRF-2 in a type I latency cell line did not activate the endogenous Qp but marginally reduced the EBNA-1 mRNA level. Switching from type III latency (Qp inactive) to type II latency (Qp active), as produced by cell fusion, is directly associated with greatly reduced expression of IRF-2. These data strongly suggest that IRF-2 is a negative regulator of Qp and may contribute to the silencing of Qp in type III latency.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10082588      PMCID: PMC84115          DOI: 10.1128/MCB.19.4.3216

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  56 in total

1.  Host-cell-phenotype-dependent control of the BCR2/BWR1 promoter complex regulates the expression of Epstein-Barr virus nuclear antigens 2-6.

Authors:  E Altiok; J Minarovits; L F Hu; B Contreras-Brodin; G Klein; I Ernberg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-01       Impact factor: 11.205

2.  The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated.

Authors:  J Sample; E B Henson; C Sample
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

3.  Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes.

Authors:  L Qu; D T Rowe
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

4.  Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated.

Authors:  H Harada; K Willison; J Sakakibara; M Miyamoto; T Fujita; T Taniguchi
Journal:  Cell       Date:  1990-10-19       Impact factor: 41.582

5.  Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation.

Authors:  B Tomkinson; E Robertson; E Kieff
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

6.  Inducible processing of interferon regulatory factor-2.

Authors:  V J Palombella; T Maniatis
Journal:  Mol Cell Biol       Date:  1992-08       Impact factor: 4.272

7.  Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system.

Authors:  N Tanaka; T Kawakami; T Taniguchi
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

8.  Resistance of human squamous carcinoma cells to transforming growth factor beta 1 is a recessive trait.

Authors:  M Reiss; T Muñoz-Antonia; J M Cowan; P C Wilkins; Z L Zhou; V F Vellucci
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

9.  Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2.

Authors:  H Harada; M Kitagawa; N Tanaka; H Yamamoto; K Harada; M Ishihara; T Taniguchi
Journal:  Science       Date:  1993-02-12       Impact factor: 47.728

10.  Constitutive expression of an ISGF2/IRF1 transgene leads to interferon-independent activation of interferon-inducible genes and resistance to virus infection.

Authors:  R Pine
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

View more
  36 in total

1.  The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity.

Authors:  H Chen; J M Lee; Y Wang; D P Huang; R F Ambinder; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  Protein-DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virus.

Authors:  D Salamon; M Takacs; D Ujvari; J Uhlig; H Wolf; J Minarovits; H H Niller
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Nuclear factor κB represses the expression of latent membrane protein 1 in Epstein-Barr virus transformed cells.

Authors:  Mingxia Cao; Qianli Wang; Amy Lingel; Luwen Zhang
Journal:  World J Virol       Date:  2014-11-12

4.  The Epstein-Barr virus-encoded LMP-1 oncoprotein negatively affects Tyk2 phosphorylation and interferon signaling in human B cells.

Authors:  Timothy R Geiger; Jennifer M Martin
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

Review 5.  IRF7: activation, regulation, modification and function.

Authors:  S Ning; J S Pagano; G N Barber
Journal:  Genes Immun       Date:  2011-04-14       Impact factor: 2.676

Review 6.  The viral etiology of AIDS-associated malignancies.

Authors:  Peter C Angeletti; Luwen Zhang; Charles Wood
Journal:  Adv Pharmacol       Date:  2008

7.  High-resolution analysis of CpG methylation and in vivo protein-DNA interactions at the alternative Epstein-Barr virus latency promoters Qp and Cp in the nasopharyngeal carcinoma cell line C666-1.

Authors:  Agnes Bakos; Ferenc Banati; Anita Koroknai; Maria Takacs; Daniel Salamon; Susanna Minarovits-Kormuta; Fritz Schwarzmann; Hans Wolf; Hans Helmut Niller; Janos Minarovits
Journal:  Virus Genes       Date:  2007-05-18       Impact factor: 2.332

8.  Autorepression of Epstein-Barr virus nuclear antigen 1 expression by inhibition of pre-mRNA processing.

Authors:  Mikio Yoshioka; Michelle M Crum; Jeffery T Sample
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

9.  The interaction between KSHV RTA and cellular RBP-Jkappa and their subsequent DNA binding are not sufficient for activation of RBP-Jkappa.

Authors:  Anil Papugani; Tricia Coleman; Clinton Jones; Luwen Zhang
Journal:  Virus Res       Date:  2007-09-11       Impact factor: 3.303

10.  Dual functions of interferon regulatory factors 7C in Epstein-Barr virus-mediated transformation of human B lymphocytes.

Authors:  Yong Zhao; Dongsheng Xu; Yanjun Jiang; Luwen Zhang
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.